ACTB and central nervous system cancer: We analyzed the pathological staining of proteins in tumor patients using the HPA database and observed that ACTB exhibits strong positivity (>75%) in glioma, head and neck cancer, liver cancer, and lung cancer and moderate positivity (75–25%) in renal cancer.